...
首页> 外文期刊>Lipids in Health Disease >A potential synbiotic product improves the lipid profile of diabetic rats
【24h】

A potential synbiotic product improves the lipid profile of diabetic rats

机译:潜在的合生素产品可改善糖尿病大鼠的脂质状况

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Previous studies showed that intake of yacon or some lactic acid bacteria was able to inhibit the development of diabetes mellitus, by reducing glucose and associated symptoms, for example, the lipid profile. Objective The purpose of this study was to assess the consumption influence of a potential symbiotic product of soybean and yacon extract and fermented Enterococcus faecium CRL 183 and Lactobacillus helveticus ssp jugurti 416 in reducing blood glucose and lipid levels in an animal model. Methods Diabetes mellitus was chemically induced by intraperitoneal administration of streptozotocin (50 mg/kg body weight). The rats were divided into four groups (n=10): GI – non-diabetic animals that received only a standard chow diet (negative control), GII – diabetic animals that received only chow diet (positive control), GIII – diabetic animals that received the chow diet?+?1 mL/kg body weight/day of soybean and yacon unfermented product, GIV – diabetic rats that received the chow diet?+?1 mL/kg body weight/day of soybean and yacon fermented product. There was a seven-week treatment period and the following parameters were evaluated: animal body weight, food and water intake, blood glucose, enzyme activities of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), triglycerides levels, total cholesterol, HDL-C, non-HDL-C. Cell viability of the fermented product was checked weekly for a seven-week period. Results The product average viable population was 108-109 CFU/mL, by ensuring both the rods and cocci regular intake. No difference was observed between the water and feed intake and body weight of groups that received unfermented and fermented products and the untreated diabetic group. The same was observed for the blood glucose and AST and ALT activities, while some improvement was observed for a lipid profile, represented by reduction of triglycerides level by 15.07% and 33.50% in groups III and IV, respectively, and an increase of 23.70% in HDL-C level for group IV. Conclusion The results showed that the ingestion of a potential symbiotic product was neither able to promote improvement in some of the disease symptoms, nor reduce blood glucose. However, a positive effect on triglycerides levels and HDL-cholesterol was observed in the groups that received the unfermented product containing yacon extract and the fermented product with Enterococcus faecium CRL 183, as well as Lactobacillus helveticus ssp jugurti 416 and yacon extract (symbiotic product).
机译:背景技术先前的研究表明,摄入Yacon或某些乳酸菌能够通过减少葡萄糖和相关症状(例如脂质分布)来抑制糖尿病的发展。目的本研究的目的是评估一种潜在的共生豆制品和大豆提取物,发酵粪便肠球菌CRL 183和瑞士乳杆菌ssp jugurti 416对降低动物血糖和脂质水平的消费影响。方法通过腹腔注射链脲佐菌素(50 mg / kg体重)化学诱导糖尿病。将大鼠分为四组(n = 10):GI –仅接受标准饮食的非糖尿病动物(阴性对照),GII –仅接受饮食的糖尿病动物(阳性对照),GIII –仅接受饮食的糖尿病动物接受大豆和Yacon发酵产品的日粮饮食+1 mL / kg体重/天,GIV –接受大豆和Yacon发酵产品的日粮饮食+1 mL / kg体重/天的糖尿病大鼠。治疗期为七个星期,评估以下参数:动物体重,食物和水的摄入量,血糖,天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)的酶活性,甘油三酸酯水平,总胆固醇,HDL- C,非HDL-C。每周检查一次发酵产物的细胞活力,持续七周。结果通过确保棒和球菌的正常摄入量,产品的平均生存种群为108-109 CFU / mL。接受未经发酵和发酵产品的组与未经治疗的糖尿病组的水,饲料摄入量和体重之间没有差异。血糖,AST和ALT活性也观察到相同,而脂质分布则有所改善,这表示第三组和第四组的甘油三酸酯水平分别降低了15.07%和33.50%,升高了23.70%第四组的HDL-C水平。结论结果表明,摄入潜在的共生产品既不能促进某些疾病症状的改善,也不能降低血糖。但是,在接受含雅康提取物和粪肠球菌CRL 183发酵产品,瑞士乳杆菌ssp jugurti 416和雅康提取物(共生产品)的未发酵产品组中,对甘油三酸酯水平和HDL-胆固醇有积极作用。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号